Expression Of HIF-1 Alpha And MT2A In Breast Cancer And Their Correlation With Prognosis

ObjectiveBreast cancer is the highest incidence of all kinds of female malignant tumors worldwide.The incidence of breast cancer is increasing year by year,which poses a great threat to women’s life and health.At present,there are many studies on the related factors of breast cancer.HIF-1 alpha and MT2A are two important factors in the progression of breast cancer However,there are few reports on the correlation between HIF-1 alpha and MT2A in China Therefore,this study explored the expression of HIF-1alpha and MT2A in breast cancer and their correlation with prognosisMethodsImmunohistochemical S-P method was used to detect the expression of MT2A and HIF-1a protein in paraffin sections of 150 cases of breast cancer.Meanwhile,the correlation between MT2A and HIF-1a protein and clinicopathological characteristics was studied by Spearman grade correlation analysis.The correlation between MT2A and HIF-1a protein expression and clinicopathological factors and prognosis was analyzed by Kaplan-Meier method and multivariate Cox回归模型 proportional hazard model.Results1.The overall 1-year survival rate was 92.00%(138/150),the 3-year survival rate was 68.00%(102/150),and the 5-year survival rate was 50.00%(75/150).2.The high expression rates of HIF-lalpha and MT2A were 3.33%and 3.33%respectively in 30 cases of benign breast tumors.There were a few stained cells in the tissues In 150 cases of breast cancer,the high expression rates of HIF-1alpha and MT2A were 41.26%(59/143)and 42.66%(61/143),which were more prominent in the nucleus.3.The expression of HIF-la and MT2A genes was only correlated with tumor size,TNM stage and axillary lymph node status,but not with other clinicopathological factors.The positive rates of HIF-1a and MT2A were 33.33%and 32.05%in tumors less than 3cm,which were significantly lower than those in other tumors.Similarly,the expression of HIF-1 a and MT2A was significantly different due to different TNM stages(P<0.05).The higher the stage,the higher the expression of HIF-1a and MT2A.The positive rates of HIF-1a and MT2A in stage Ⅰ cases were 10.00%and 10.00%respectively,which were much lower than those in other TNM stages.In axillary lymph node negative group,the expression rates of HIF-la and MT2A were 1 3.79%and 15.52%,which were lower than 58.82%and 57.65%in axillary lymph node positive group.In conclusion,the positive expression rates of HIF-1a and MT2A protein increased with the increase of tumors,TNM clinical stage and axillary lymph node metastasis.4.Univariate analysis showed that age,tumor size,clinical stage,lymph node status,distant metastasis and expression of HIF-1 alpha and MT2A genes had significant effects on the prognosis of breast cancer(P<0.05).5.Cox proportional hazard model was used to analyze prognostic factors such as age,menstrual status,tumor size,pathological type,clinical stage,axillary lymph node metastasis.distant metastasis,ER,PR,HIF-lalpha and MT2A.Finally,clinical scores of HIF-1 alpha,MT2A and TNM were selected.Stage and lymph node metastasis were selected into the model.These four factors were closely related to the prognosis of breast cancer and had independent prognostic significance.Among them,axillary lymph node was positive,which reflected the most risk factors for adverse prognosis.The risk was 1.772(P<0.05),followed by clinical staging,which had a poor prognosis,with a risk of 1.003(P<0.05),while HIF-la had an independent prognostic significance.The risk of MT2A positive expression was 0.341 and 0.382(P<0.05).Conclusions1.In breast cancer,the high expression of HIF-la and MT2A is correlated with TNM staging and lymph node metastasis,and there is a positive correlation between them.The combined detection of HIF-la and MT2A can be used as an important detection standard for lymph node metastasis and TNM staging.2.HIF-1a,MT2A protein expression,lymph node metastasis and TNM stage may be independent prognostic indicators of breast cancer.Detection of HIF-la and MT2A is helpful for screening patients with high risk factors of recurrence and metastasis,as a clinical treatment guidance tool.